Related references
Note: Only part of the references are listed.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer
Daniela E. Matei et al.
GYNECOLOGIC ONCOLOGY (2010)
Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis
Yanfang Li et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2009)
The promises and pitfalls of epigenetic therapies in solid tumours
Janet S. Graham et al.
EUROPEAN JOURNAL OF CANCER (2009)
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
Roger M. Lyons et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Differential Methylation Profile of Ovarian Cancer in Tissues and Plasma
Anatoliy Melnikov et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage
George S. Watts et al.
BMC MEDICAL GENOMICS (2008)
Pharmaceutical management of ovarian cancer - Current status
Maurie Markman
DRUGS (2008)
DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma
Qinghua Feng et al.
GYNECOLOGIC ONCOLOGY (2008)
DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment
Caroline A. Barton et al.
GYNECOLOGIC ONCOLOGY (2008)
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer
Pedro T. Ramirez et al.
GYNECOLOGIC ONCOLOGY (2008)
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
Kim Appleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
M. Candelaria et al.
ANNALS OF ONCOLOGY (2007)
Alternate molecular genetic pathways in ovarian carcinomas of common histological types
Julia Willner et al.
HUMAN PATHOLOGY (2007)
Identification of candidate methylation-responsive genes in ovarian cancer
Laura Menendez et al.
MOLECULAR CANCER (2007)
The management of recurrent ovarian cancer
Ronald M. Bukowski et al.
SEMINARS IN ONCOLOGY (2007)
Cancer epigenomics: DNA methylomes and histone-modification maps
Manel Esteller
NATURE REVIEWS GENETICS (2007)
Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 ovarian cancer cell lines
Masayoshi Imura et al.
CANCER LETTERS (2006)
Antimitogenic and chernosensitizing effects of the methylation inhibitor zebularine in ovarian cancer
C Balch et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Promoter hypermethylation profile of ovarian epithelial neoplasms
PB Makarla et al.
CLINICAL CANCER RESEARCH (2005)
Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer
P Horak et al.
MOLECULAR CANCER RESEARCH (2005)
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance
HT See et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients
G Gifford et al.
CLINICAL CANCER RESEARCH (2004)
Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types
N Shivapurkar et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy
MM Leitao et al.
GYNECOLOGIC ONCOLOGY (2003)
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells
I Rhee et al.
NATURE (2002)
Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes
G Strathdee et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Share Paper
